Phaseline

Companies › Conjupro Biotherapeutics

Conjupro Biotherapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CPO301
antibody drug conjugate
–Phase 1CancerMay 2027
JMT108
Bispecific antibody
–Phase 1CancerJul 2029
SYS6043
Anti-B7-H3 antibody-drug conjugate
B7H3Phase 1CancerDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05948865CPO301Phase 1CancerOncologyMay 2027
NCT07317505JMT108Phase 1CancerOncologyJul 2029
NCT07424547SYS6043Phase 1CancerOncologyDec 2029

From the company's SEC filings

Complete response letters from FDA

Targets

B7H3 (1)

Companies with the same targets

BioNTech SE Hansoh BioMedical R&D Company Daiichi Sankyo Qilu Pharmaceutical IDEAYA Biosciences MediLink Therapeutics (Suzhou) CSPC Megalith Biopharmaceutical Phrontline Biopharma Aktis Oncology NEOK Bio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.